Life Sciences
Top stories summarized by our editors
8/21/2017

The Indian Council of Medical Research will conduct research with the International Vaccine Institute into new vaccines to combat infectious diseases. Potential vaccine targets are tuberculosis, malaria, dengue and chikungunya.

8/21/2017

The FDA granted orphan drug status to Curtana Pharmaceuticals' CT-179, intended for the treatment of brain tumors in children and glioblastoma in adults.

8/21/2017

The early-stage clinical trial that will evaluate the efficacy and safety of UCART123, Cellectis' chimeric antigen receptor T-cell product, in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm has progressed with the company's announcement that the first participant has been dosed. The trial will assess the effects of the cell therapy on patients with BPDCN who are in the relapsed, refractory or frontline stages of the disease.

More Summaries:
Cellectis
8/21/2017

Maviret, AbbVie's glecaprevir/pibrentasvir drug developed as a treatment for adults with chronic hepatitis C virus across genotypes 1-6, received approval from Health Canada.

8/21/2017

A pilot study using nonhuman primates as subjects will be launched by the Armed Forces Radiobiology Research Institute of the Department of Defense to determine the efficacy of Pluristem Therapeutics' PLX-R18 as a therapy for acute radiation syndrome when given before or during the first 24 hours of being exposed to radiation.

8/21/2017

A development deal was closed by Ascletis to license the manufacture of Medivir's hepatitis C virus drug candidate MIV-802 in China, consisting of areas in mainland China, Hong Kong, Macau and Taiwan. No financial details were disclosed except for confirmation that Medivir is to receive an upfront payment as well as development and commercialization milestones, plus tiered royalties of sold products that contain MIV-802.

More Summaries:
China, Ascletis, Medivir, Hong Kong, Medivir
8/21/2017

A round of Series B financing raised $151 million for Unity Biotechnology. The company is developing drugs for the treatment of diseases related to age such as atherosclerosis, osteoarthritis, eye diseases and kidney disease.

Full Story:
BioCentury
8/21/2017

British biotech company Oxitec's "friendly" mosquito carries a self-limiting gene that causes offspring to die before reaching adulthood. Release trials have seen population reductions of at least 90 percent, and two Brazilian municipalities experienced a reduction in dengue fever cases from 133 per year to one.

Full Story:
The Hill
8/21/2017

The NATO Science for Peace and Security Program funded a three-year research project in Serbia to produce biofuel derived from algae for the purpose of improving energy security. "I expect that our results will encourage the development of green technologies in the energy sector," said project leader Ivan Spasojevic, who added that completion of the project could result in fuel prices dropping by a fifth over the next five years.

Full Story:
Biofuels Digest
8/21/2017

A bill that reauthorizes the FDA's user fee program for medical devices, drugs and biosimilars was signed into law by President Donald Trump. The FDA Reauthorization Act of 2017 includes provisions for improving the FDA's financial transparency and accountability, enhances the agency's hiring ability and requires existing efforts for integrating real-world evidence and patient perspectives into regulatory decision-making to be extended.

More Summaries:
FDA, President Donald Trump